Δημοσίευση στις Jun 2019 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/31054483/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=36

 

Guy De Backer 

, Piotr Jankowski 

, Kornelia Kotseva 

, Erkin Mirrakhimov 

, Željko Reiner 

, Lars Rydén 

, Lale Tokgözoğlu 

, David Wood 

, Dirk De Bacquer 

, EUROASPIRE V collaborators, Writing Committee, Scientific Steering/ Executive Committee, Coordinating centre, Diabetes centre, Data management centre, Statistical analysis centre, Central laboratory, Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk


Background and aims:

One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients.


Methods:

Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT.


Results:

At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes.


Conclusions:

The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient.


Keywords:

Coronary heart disease; Dyslipidaemia; EUROASPIRE; LDL-Cholesterol; Lipid lowering therapy; Secondary prevention.

error: